Switzerland Archives

News and Trends 17 Oct 2022

Ophthalmology biopharma company Oculis combines with EBAC

Oculis, SA, a global biopharmaceutical company developing treatments to save sight and improve eye care and European Biotech Acquisition Corp (EBAC), a special purpose acquisition company (SPAC), have entered into…

October 17, 2022 - 5 minutesmins - By Jim Cornall

CRISPR Therapeutics, CRISPR-Cas9, genome editing, biotech

News and Trends 17 Oct 2022

CRISPR/Cas9: Challenges and outlook from an investor’s perspective

A Q&A with Fady Riad, CEO of consulting company Centurion Life Sciences. How did CRISPR/Cas9 revolutionize gene editing and the broader life sciences industry? CRISPR/Cas9 is undoubtedly one of the…

October 17, 2022 - 6 minutesmins - By External Contributor

News and Trends 14 Oct 2022

Beyond Biotech podcast 18: BiotechX, Cultivated Biosciences, EPFL, Faron Pharmaceuticals

This week, we have four interviews. Our guests are: Juho Jalkanen, COO of Faron Pharmaceuticals; Ardemis Boghossian and Melania Reggente from the EPFL School of Basic Sciences in Switzerland; Tomas…

October 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 3 Oct 2022

Roche launches next-generation SARS-CoV-2 Rapid Antibody Test

Roche has launched the SARS-CoV-2 Rapid Antibody Test 2.0 in markets accepting the CE Mark. The test is the next generation of Roche's existing SARS-CoV-2 Rapid Antibody Test, which launched…

October 3, 2022 - 4 minutesmins - By Jim Cornall

Biodiversity Genomic Europe project will tackle biodiversity crisis

News and Trends 28 Sep 2022

Project to tackle biodiversity crisis using the power of DNA data and genomics launched

A project to tackle the biodiversity crisis using DNA data, genomic science that will fundamentally change conservation science and policy has been launched by European experts. The new pan-European Biodiversity…

September 28, 2022 - 4 minutesmins - By Liza Laws

News and Trends 22 Sep 2022

Study data for glioblastoma treatment confirms safety and tolerability profile

The final results of a phase 1/2 study of a therapy in recurrent glioblastoma multiforme (GBM) have been reported by Australian-based Telix Pharmaceuticals Ltd. The therapy, TLX101 (4-L-[ 131I] iodo-phenylalanine, or 131I-IPA)…

September 22, 2022 - 4 minutesmins - By Liza Laws

News and Trends 22 Sep 2022

Swiss scientists reduce resistance of dormant melanoma cells

Small-molecule targeted therapies revolutionized the treatment of metastatic melanoma, provided that the tumors carry the mutations to respond to these treatments. However, despite an initial response that can be seen…

September 22, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 20 Sep 2022

ten23 health completes superstructure of new sterile production facility

ten23 health, a global contract development and manufacturing organization (CDMO) has completed the superstructure of its new sterile manufacturing facility. The existing facility of ten23 health’s swissfillon AG company in…

September 20, 2022 - 2 minutesmins - By Jim Cornall

glioblastoma oncolytic virus transgene 2

News and Trends 20 Sep 2022

Collaboration to develop new glioblastoma combination therapy nets €1.06M

Dutch biotech CimCure B.V., French biotech company Covalab, Amsterdam UMC (The Netherlands) and the University of Zurich (Switzerland), have received a €1.06M ($1.08M) grant from EUREKA Eurostars. With a total…

September 20, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 19 Sep 2022

GENFIT to acquire Versantis to expand liver disease portfolio

GENFIT has entered into an exclusivity agreement with a view to acquire all the share capital and voting rights of Versantis, a private Swiss-based clinical stage biotechnology company focused on…

September 19, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

Could combining biotech and photosynthetic cyanobacteria help the energy crisis?

A group of researchers in Switzerland is using photosynthetic bacteria to generate energy. After implanting nanotubes into them, the bacteria can create energy. And when the cells divide, those nanotubes…

September 12, 2022 - 6 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

Cuffless device worn 24/7 can lower blood pressure, says Aktiia

A company making cuffless monitors for blood pressure says a significant and sustained reduction has been achieved for patients wearing the monitor 24/7. The device, made by Aktiia, measures blood…

September 12, 2022 - 2 minutesmins - By Liza Laws

News and Trends 8 Sep 2022

Cultivated Biosciences raises $1.5M to take fats to the next frontier

Cultivated Biosciences, an ingredient startup biotech company founded by Swiss entrepreneurs Tomas Turner and Dimitri Zogg, has just raised a $1.5M pre-seed round. The funding will enable the growing team…

September 8, 2022 - 2 minutesmins - By Jim Cornall

In Depth 7 Sep 2022

The biggest private biotech investments in August 2022

The healthcare-focused companies Orna Therapeutics, F2G and Sironax bagged the biggest biotech investments in August 2022, with mRNA vaccines, genomics and fermentation technology attracting big funding rounds. As many took…

September 7, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 1 Sep 2022

Labiotech adds conference and event listings

In the past few months, Labiotech.eu has boosted its coverage range to go global, added a podcast, expanded to three weekly newsletters, introduced special monthly newsletters, and now we've added…

September 1, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 31 Aug 2022

Researchers identify possible target for type of sporadic ALS

Researchers have published two papers describing how they identified a potential new pathway for treating a sporadic form of amyotrophic lateral sclerosis (ALS). The studies were published as part of…

August 31, 2022 - 3 minutesmins - By Jim Cornall

Interview 31 Aug 2022

How CDMOs keep pace with trends in advanced therapies

Advanced therapies including cell and gene therapies are exploding in demand, but the manufacturing process can be difficult. Jean-Christophe Hyvert, president of biologics and cell & gene at the CDMO…

August 31, 2022 - 8 minutesmins - By Jonathan Smith

News and Trends 29 Aug 2022

Marketing authorization granted for treatment of serious retinal diseases

The European Commission has granted marketing authorization to Ranivisio, a treatment for several serious retinal diseases. Polpharma Biologics Group BV, Formycon AG and their Swiss joint venture, Bioeq AG, announced…

August 29, 2022 - 3 minutesmins - By Liza Laws

In Depth 23 Aug 2022

Company’s 3D microchip gives mechanistic insights into human brain

A microchip that allows scientists to study the complexity of 3D cellular networks at unrivaled scale and precision has been added to 3Brain AG’s brain-on-chip portfolio. In collaboration with Swiss…

August 23, 2022 - 5 minutesmins - By Liza Laws

News and Trends 22 Aug 2022

Drug to treat rare kidney disease to be reviewed by EMA

The European Medicines Agency (EMA) has agreed to review a conditional marketing authorization (CMA) application for a drug to treat a rare kidney disorder. The news was announced today (August…

August 22, 2022 - 3 minutesmins - By Liza Laws

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering